develops cardiovascular drugs with a focus on the treatment of atrial arrhythmias and congestive heart failure.
It has one completed and two ongoing Phase III clinical trials in collaboration with Fujisawa Healthcare, Inc., its collaborative partner for RSD1235 (iv) for the acute treatment of atrial fibrillation and atrial flutter.
The company’s other development stage products comprise RSD1235, a chemical entity designed to treat atrial fibrillation; and Oxypurinol, an inhibitor of xanthine oxidase, for the treatment of congestive heart failure.
In addition, Cardiome Pharma has licenses and collaborative research agreements with the University of British Columbia, The Johns Hopkins University, and Genzyme Corp.
The company was incorporated in 1986 as Nortran Resources, Ltd.
and changed its name to Nortran Pharmaceuticals, Inc.
in 1992.
Further, it changed its name to Cardiome Pharma Corp.
in 2001.
Cardiome Pharma is headquartered in Vancouver, Canada.
